Cited by 373Regulation of Appetite and ObesityPharmacology and Obesity TreatmentDiabetes Treatment and Management

The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.

Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity

Open access

Silva, Akila De, Bloom, Stephen R.·2012·Gut and Liver

DOI 10.5009/gnl.2012.6.1.10PMC PMC3286726

Open this paper in CoChat — free account

Abstract

The global obesity epidemic has resulted in significant morbidity and mortality. However, the medical treatment of obesity is limited. Gastric bypass is an effective surgical treatment but carries significant perioperative risks. The gut hormones, peptide tyrosine tyrosine (PYY) and glucagon-like peptide 1 (GLP-1), are elevated following gastric bypass and have been shown to reduce food intake. They may provide new therapeutic targets. This review article provides an overview of the central control of food intake and the role of PYY and GLP-1 in appetite control. Key translational animal and human studies are reviewed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.5009/gnl.2012.6.1.10

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451
A Potential Decline in Life Expectancy in the United States in the 21st Century
Olshansky, S. J., Passaro, D. J., Hershow, R. C., Layden, J., Carnes, B. A., Brody, J., Hayflick, L., Butler, R. N., Allison, D. B., & Ludwig, D. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmsr043743 · Cited by 2,612
Long-term mortality after gastric bypass surgery
Adams, T. D., Gress, R. E., Smith, S. C., Halverson, R. C., Simper, S. C., Rosamond, W. D., LaMonte, M. J., Stroup, A. M., & Hunt, S. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066603 · Cited by 2,572
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Self-citation
The human orbitofrontal cortex: linking reward to hedonic experience
Kringelbach, M. L. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1747 · Cited by 2,180
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Self-citation
A Potential Decline in Life Expectancy in the United States in the 21st Century
Olshansky, S. J., Passaro, D. J., Hershow, R. C., Layden, J. E., Carnes, B. A., Brody, J. A., Hayflick, L., Butler, R. N., Allison, D. B., & Ludwig, D. S. (2005) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000167407.83915.e7 · Cited by 1,947
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Self-citation
Brain Lesions, Obesity, and Other Disturbances in Mice Treated with Monosodium Glutamate
Olney, J. (1969) · Science · doi:10.1126/science.164.3880.719 · Cited by 1,885
Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604
Self-citation
Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120
Hirasawa, A., Tsumaya, K., Awaji, T., Katsuma, S., Adachi, T., Yamada, M., Sugimoto, Y., Miyazaki, S., & Tsujimoto, G. (2004) · Nature Medicine · doi:10.1038/nm1168 · Cited by 1,580
Meta-Analysis: Surgical Treatment of Obesity
Maggard, M. A., Shugarman, L. R., Suttorp, M. J., Maglione, M., Sugerman, H. J., Livingston, E. H., Nguyen, N. T., Li, Z., Mojica, W., Hilton, L. G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-7-200504050-00013 · Cited by 1,567
Hypothalamic CART is a new anorectic peptide regulated by leptin
Kristensen, P. L., Judge, M. E., Thim, L., Ribel, U., Christjansen, K. N., Wulff, B. S., Clausen, J. T., Jensen, P. B., Madsen, O. D., Vrang, N., et al. (1998) · Nature · doi:10.1038/29993 · Cited by 1,282
NEUROPEPTIDE Y AND HUMAN PANCREATIC POLYPEPTIDE STIMULATE FEEDING BEHAVIOR IN RATS
Clark, J. T., Kalra, P. S., Crowley, W. R., & Kalra, S. P. (1984) · Endocrinology · doi:10.1210/endo-115-1-427 · Cited by 1,276
Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Human distribution and release of a putative new gut hormone, peptide YY
Adrian, T. E., Ferri, G., Bacarese-Hamilton, A. J., Fuessl, H. S., Polak, J. M., & Bloom, S. R. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90211-2 · Cited by 1,064
Self-citation
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60888-4 · Cited by 1,036
Gut Hormone Profiles Following Bariatric Surgery Favor an Anorectic State, Facilitate Weight Loss, and Improve Metabolic Parameters
Roux, C. W. L., Aylwin, S. J. B., Batterham, R. L., Borg, C. M., Coyle, F., Prasad, V., Shurey, S., Ghatei, M. A., Patel, A. G., & Bloom, S. R. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000183349.16877.84 · Cited by 985
Self-citation
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 916
Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)
Marre, M., Shaw, J. E., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M. D., Thi, T. D. L., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 821
Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass
le Roux, C. W., Welbourn, R., Werling, M., Osborne, A., Kokkinos, A., Laurenius, A., Lönroth, H., Fändriks, L., Ghatei, M. A., Bloom, S. R., et al. (2007) · Annals of Surgery · doi:10.1097/sla.0b013e3180caa3e3 · Cited by 741 · cited 1×
“Significantly, inhibiting the PYY and GLP-1 responses results in return of appetite and increases food intake.(29) Therefore, it is likely that elevated levels of PYY and GLP-1 play a key role in the sustained weight loss observed following gastric bypass surgery.”
BackgroundSelf-citation
A Meta-Analysis of the Effect of Glucagon-Like Peptide-1 (7-36) Amide on Ad Libitum Energy Intake in Humans
Verdich, C., Flint, A., Gutzwiller, J., Näslund, E. B., Beglinger, C., Hellström, P. M., Long, S. J., Morgan, L., Holst, J. J., & Astrup, A. V. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7877 · Cited by 657
Leptin Regulates Striatal Regions and Human Eating Behavior
Farooqi, I. S., Bullmore, E., Keogh, J., Gillard, J., O'Rahilly, S., & Fletcher, P. C. (2007) · Science · doi:10.1126/science.1144599 · Cited by 622
The inhibitory effects of peripheral administration of peptide YY3–36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal–brainstem–hypothalamic pathway
Abbott, C. R., Monteiro, M. P., Small, C. J., Sajedi, A., Smith, K. L., Parkinson, J. R. C., Ghatei, M. A., & Bloom, S. R. (2005) · Brain Research · doi:10.1016/j.brainres.2005.03.011 · Cited by 617
Self-citation
Gpr40 Is Expressed in Enteroendocrine Cells and Mediates Free Fatty Acid Stimulation of Incretin Secretion
Edfalk, S., Steneberg, P., & Edlund, H. (2008) · Diabetes · doi:10.2337/db08-0307 · Cited by 587
A C-Terminal Fragment of Agouti-Related Protein Increases Feeding and Antagonizes the Effect of Alpha-Melanocyte Stimulating Hormone in Vivo
Rossi, M., Kim, M. S., Morgan, D. G. A., Small, C. J., Edwards, C. M. B., Sunter, D., Abusnana, S., Goldstone, A. P., Russell, S. H., Stanley, S. A., et al. (1998) · Endocrinology · doi:10.1210/endo.139.10.6332 · Cited by 576 · cited 1×
“Furthermore, AgRP is a competitive antagonist at melanocortin receptors.(15) CART is thought to have either orexigenic or anorexigenic effects depending on its site of action; central intracerebroventricular administration of CART reduces food intake in rats,(16) whereas administration of CART directly into the ARC in…”
BackgroundSelf-citation
Cloning and Functional Expression of the Human Islet GLP-1 Receptor: Demonstration That Exendin-4 Is an Agonist and Exendin-(9–39) an Antagonist of the Receptor
Thorens, B., Porret, A., Bühler, L. H., Deng, S., Morel, P., & Widmann, C. (1993) · Diabetes · doi:10.2337/diab.42.11.1678 · Cited by 555
Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502
PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans
Batterham, R. L., Ffytche, D. H., Rosenthal, J., Zelaya, F. O., Barker, G. J., Withers, D. J., & Williams, S. (2007) · Nature · doi:10.1038/nature06212 · Cited by 489
Recent advances in understanding leptin signaling and leptin resistance
Morris, D. L., & Rui, L. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00274.2009 · Cited by 484
Tissue-specific expression of the human receptor for glucagon-like peptide-I: Brain, heart and pancreatic forms have the same deduced amino acid sequences
Wei, Y., & Mojsov, S. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01430-9 · Cited by 450
The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats
Koda, S., Date, Y., Murakami, N., Shimbara, T., Hanada, T., Toshinai, K., Niijima, A., Furuya, M., Inomata, N., Osuye, K., et al. (2005) · Endocrinology · doi:10.1210/en.2004-1266 · Cited by 431
GPR119 Is Essential for Oleoylethanolamide-Induced Glucagon-Like Peptide-1 Secretion From the Intestinal Enteroendocrine L-Cell
Lauffer, L. M., Iakoubov, R., & Brubaker, P. L. (2009) · Diabetes · doi:10.2337/db08-1237 · Cited by 405
A Role for Intestinal Endocrine Cell-Expressed G Protein-Coupled Receptor 119 in Glycemic Control by Enhancing Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Peptide Release
Chu, Z., Carroll, C., Alfonso, J., Gutierrez, V., He, H., Lucman, A., Pedraza, M., Mondala, H., Gao, H., Bagnol, D., et al. (2008) · Endocrinology · doi:10.1210/en.2007-0966 · Cited by 387
Hypothalamic paraventricular nucleus lesions produce overeating and obesity in the rat
LEIBOWITZ, S. F., Hammer, N. J., & Chang, K. (1981) · Physiology & Behavior · doi:10.1016/0031-9384(81)90366-8 · Cited by 384
Paraventricular nucleus injections of peptide YY and neuropeptide Y preferentially enhance carbohydrate ingestion
Stanley, B. G., Daniel, D., Chin, A. S., & LEIBOWITZ, S. F. (1985) · Peptides · doi:10.1016/0196-9781(85)90452-8 · Cited by 383
Effect of Peptide YY3–36 on Food Intake in Humans
Degen, L. P., Oesch, S., Casanova, M., Graf, S., Ketterer, S., Drewe, J., & Beglinger, C. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.09.001 · Cited by 375
Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure
Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.063 · Cited by 372
Peptide YY3–36 and Glucagon-Like Peptide-17–36 Inhibit Food Intake Additively
Neary, N. M., Small, C. J., Druce, M. R., Park, A. J., Ellis, S. M., Semjonous, N. M., Dakin, C. L., Filipsson, K., Wang, F., Kent, A. S., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0237 · Cited by 371
Self-citation
Two molecular forms of Peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1–36 and PYY 3–36
Grandt, D., Schimiczek, M., Beglinger, C., Layer, P., Goebell, H., Eysselein, V. E., & Reeve, J. R. (1994) · Regulatory Peptides · doi:10.1016/0167-0115(94)90204-6 · Cited by 363
A Meta-Analysis of the Effect of Glucagon-Like Peptide-1 (7-36) Amide on Ad Libitum Energy Intake in Humans
Verdich, C. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.9.4382 · Cited by 340
Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety
Borg, C.-M., le Roux, C. W., Ghatei, M. A., Bloom, S. R., Patel, A. G., & Aylwin, S. J. B. (2006) · British journal of surgery · doi:10.1002/bjs.5227 · Cited by 325
Self-citation
Central Administration of Glucagon-Like Peptide-1 Activates Hypothalamic Neuroendocrine Neurons in the Rat
Larsen, P. J., Tang‐Christensen, M., & Jessop, D. S. (1997) · Endocrinology · doi:10.1210/endo.138.10.5270 · Cited by 317
Weight Regain in U.S. Adults Who Experienced Substantial Weight Loss, 1999–2002
Weiss, E. C., Galuska, D. A., Kettel Khan, L., Gillespie, C., & Serdula, M. K. (2007) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2007.02.040 · Cited by 307
Ascending projections from the solitary tract nucleus to the hypothalamus. A Phaseolus vulgaris lectin tracing study in the rat
Horst, G. J. T., Boer, P. D., Luiten, P. G. M., & van Willigen, J. D. (1989) · Neuroscience · doi:10.1016/0306-4522(89)90441-7 · Cited by 296
The role of gastrointestinal vagal afferents in the control of food intake: current prospects
Schwartz, G. J. (2000) · Nutrition · doi:10.1016/s0899-9007(00)00464-0 · Cited by 294
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Diabetes Care (2009) 32, (1224-1230))
Zinman, B., Gerich, J. E., Buse, J. B., Lewin, A., Schwartz, S. E., Raskin, P., Hale, P. M., Zdravkovic, M. D., & Blonde, L. (2010) · Diabetes Care · Cited by 290
Effects of PYY1–36and PYY3–36on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects
Sloth, B., Holst, J. J., Flint, A., Gregersen, N. T., & Astrup, A. V. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00450.2006 · Cited by 250
Role of the Y1 Receptor in the Regulation of Neuropeptide Y-Mediated Feeding: Comparison of Wild-Type, Y1 Receptor-Deficient, and Y5 Receptor-Deficient Mice
Kanatani, A., Mashiko, S., Murai, N., Sugimoto, N., Itô, J., Fukuroda, T., Fukami, T., Morin, N. R., MacNeil, D. J., der Ploeg, L. H. T. V., et al. (2000) · Endocrinology · doi:10.1210/endo.141.3.7387 · Cited by 250
Orexin Signaling in the Ventral Tegmental Area Is Required for High-Fat Appetite Induced by Opioid Stimulation of the Nucleus Accumbens
Zheng, H., Patterson, L. M., & Berthoud, H.-R. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3542-07.2007 · Cited by 248
Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes
Green, B. D., Flatt, P. R., & Bailey, C. J. (2006) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2006.024 · Cited by 233
Small-molecule agonists for the glucagon-like peptide 1 receptor
Knudsen, L. B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J. T., Holst, J. J., Jeppesen, C. B., Johnson, M. D., de Jong, J. C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605701104 · Cited by 232
Long‐term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over‐weight metformin‐treated patients with type 2 diabetes mellitus
Ratner, R. E., Maggs, D., Nielsen, L. L., Stonehouse, A. H., Poon, T., Zhang, B., Bicsak, T. A., Brodows, R. G., & Kim, D. D. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00589.x · Cited by 217
Amygdalo-Hypothalamic Circuit Allows Learned Cues to Override Satiety and Promote Eating
Petrovich, G. D., Setlow, B., Holland, P. C., & Gallagher, M. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-19-08748.2002 · Cited by 208
Descending pathways from hypothalamus to dorsal motor vagus and ambiguus nuclei in the rat
Horst, G. J. T., Luiten, P., & Kuipers, F. (1984) · Journal of the Autonomic Nervous System · doi:10.1016/0165-1838(84)90008-0 · Cited by 182
Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus.
Shughrue, P. J., Lane, M. V., & Merchenthaler, I. J. (1996) · Endocrinology · doi:10.1210/endo.137.11.8895391 · Cited by 175
Gastrointestinal targets of appetite regulation in humans
Delzenne, N. M., Blundell, J. E., Brouns, F. J. P. H., Cunningham, K., de Graaf, K. C., Erkner, A., Lluch, A., Mars, M., Peters, H. P. F., & Westerterp‐Plantenga, M. S. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00707.x · Cited by 172
A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db / db mice
Chen, D., Liao, J., Li, N., Zhou, C., Liu, Q., Wang, G., Zhang, R., Zhang, S., Lin, L., Chen, K., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610173104 · Cited by 171
Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults
Gantz, I., Erondu, N., Mallick, M., Musser, B., Krishna, R., Tanaka, W. K., Snyder, K., Stevens, C., Stroh, M. A., Zhu, H., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1806 · Cited by 163
Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects
Näslund, E. B., King, N. A., Mansten, S., Adner, N., Holst, J. J., Gutniak, M., & Hellström, P. M. (2004) · British Journal Of Nutrition · doi:10.1079/bjn20031064 · Cited by 160
Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans
Pannacciulli, N., Le, D. S. N. T., Salbe, A. D., Chen, K., Reiman, E. M., Tataranni, P. A., & Krakoff, J. A. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2006.12.035 · Cited by 159
Evidence of an Orexigenic Role for Cocaine- and Amphetamine-Regulated Transcript after Administration into Discrete Hypothalamic Nuclei
Abbott, C. R., Rossi, M., Wren, A., Murphy, K. G., Kennedy, A. R., Stanley, S. A., Zollner, A. N., Morgan, D. G. A., Morgan, I., Ghatei, M. A., et al. (2001) · Endocrinology · doi:10.1210/endo.142.8.8304 · Cited by 158
Self-citation
Energy Expenditure, Satiety, and Plasma Ghrelin, Glucagon-Like Peptide 1, and Peptide Tyrosine-Tyrosine Concentrations following a Single High-Protein Lunch
Smeets, A. J. P. G., Soenen, S., Luscombe‐Marsh, N. D., Ueland, Ø., & Westerterp‐Plantenga, M. S. (2008) · Journal of Nutrition · doi:10.1093/jn/138.4.698 · Cited by 151
Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials
Hutton, B., & Fergusson, D. A. (2004) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/80.6.1461 · Cited by 149
Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans
Ørskov, C., Rabenhøj, L., Wettergren, A., et al. (1994) · Diabetes · doi:10.2337/diabetes.43.4.535 · Cited by 143
Distribution of the neuropeptide Y Y2 receptor mRNA in rat central nervous system
Gustafson, E. L., Smith, K. E., Durkin, M. M., Walker, M. W., Gerald, C., Weinshank, R. L., & Branchek, T. A. (1997) · Molecular Brain Research · doi:10.1016/s0169-328x(97)00017-x · Cited by 140
Peptide YY (PYY), a poteny orexigenic agent
Morley, J. E., Levine, A. S., Grace, M. K., & Kneip, J. M. (1985) · Brain Research · doi:10.1016/0006-8993(85)91490-8 · Cited by 137
Effect of Macronutrient Composition on Postprandial Peptide YY Levels
Essah, P. A., Levy, J. R., Sistrun, S. N., Kelly, S. M., & Nestler, J. E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2273 · Cited by 133
Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin
Riddle, M. C., Henry, R. R., Poon, T., Bei, Z., Mac, S. M., Holcombe, J. H., Kim, D. D. H., & Maggs, D. G. (2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.646 · Cited by 127
Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor
Thorens, B., Porret, A., Buhler, L., et al. (1993) · Diabetes · doi:10.2337/diabetes.42.11.1678 · Cited by 126
Characterization of neuropeptide Y binding sites in rat brain membrane preparations using [125I][Leu31,Pro34]peptide YY and [125I]peptide YY3-36 as selective Y1 and Y2 radioligands.
Dumont, Y., Fournier, A., St-Pierre, S. A., & Quirion, R. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24459-7 · Cited by 125
Eating for pleasure or calories
Zheng, H., & Berthoud, H. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.10.011 · Cited by 121
The neurocognitive bases of human multimodal food perception: Consciousness
Verhagen, J. V. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.09.002 · Cited by 110
Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects
Steinert, R. E., Poller, B., Castelli, M., Drewe, J., & Beglinger, C. (2010) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2010.29663 · Cited by 94
PYY(3–36) induces Fos in the arcuate nucleus and in both catecholaminergic and non-catecholaminergic neurons in the nucleus tractus solitarius of rats
Blevins, J. E., Chelikani, P. K., Haver, A. C., & Reidelberger, R. D. (2007) · Peptides · doi:10.1016/j.peptides.2007.11.003 · Cited by 73
Variation of Postprandial PYY3–36Response following Ingestion of Differing Macronutrient Meals in Obese Females
Helou, N., Obeid, O., Azar, S. T., & Hwalla, N. C. (2008) · Annals of Nutrition and Metabolism · doi:10.1159/000138122 · Cited by 70
GPR119: “Double-Dipping” for Better Glycemic Control
Lauffer, L., Iakoubov, R., & Brubaker, P. L. (2008) · Endocrinology · doi:10.1210/en.2008-0182 · Cited by 55
Molecular Forms of Glucagon-Like Immunoreactivity in Porcine Intestine and Pancreas*
Ghatei, M. A., UTTENTHAL, L. O., Bryant, M. G., Christofides, N. D., MOODY, A. J., & Bloom, S. R. (1983) · Endocrinology · doi:10.1210/endo-112-3-917 · Cited by 52
Self-citation
Antiobesity Surgery in Sweden From 1980 to 2005
Marsk, R., Freedman, J., Tynelius, P., Rasmussen, F. E., & Näslund, E. B. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e318189b0cf · Cited by 49
Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus
Shughrue, P. J. (1996) · Endocrinology · doi:10.1210/en.137.11.5159 · Cited by 49
[Cellular localization, half-life, and secretion of peptide YY].
Lluı́s, F., Fujimura, M., Gómez, G., Salvá, J. A., Greeley, G. H., & Thompson, J. C. (1989) · PubMed · Cited by 18
A tasty morsel: the role of the dorsal vagal complex in the regulation of food intake and swallowing. Focus on “BDNF/TrkB signaling interacts with GABAergic system to inhibit rhythmic swallowing in the rat,” by Bariohay et al.
Bailey, E. F. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.90701.2008 · Cited by 14
Untitled work
Matelli (1998) · doi:10.1002/(sici)1096-9861(19981221)402:3

Flagged first, then by citations

Research works printed but not linked: 7

Rossi, 1998, Endocrinology, 139, 4428, 10.1210/en.139.10.4428 · DOI · Paper page
Abbott, 2001, Endocrinology, 142, 3457, 10.1210/en.142.8.3457 · DOI
Lluis, 1989, Rev Esp Fisiol, 45, 377
Kanatani, 2000, Endocrinology, 141, 1011, 10.1210/en.141.3.1011 · DOI
Kieffer, 1995, Endocrinology, 136, 3585, 10.1210/en.136.8.3585 · DOI · Paper page
Willms, 1996, J Clin Endocrinol Metab, 81, 327, 10.1210/jc.81.1.327 · DOI · Paper page
Larsen, 1997, Endocrinology, 138, 4445, 10.1210/en.138.10.4445 · DOI

Sorted by citations

The Microbiota-Gut-Brain Axis
Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00018.2018 · Cited by 5,286
Short-chain fatty acids in control of body weight and insulin sensitivity
Canfora, E. E., Jocken, J. W., & Blaak, E. E. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.128 · Cited by 2,298
The role of microbial amino acid metabolism in host metabolism
Neis, E., Dejong, C., & Rensen, S. (2015) · Nutrients · doi:10.3390/nu7042930 · Cited by 920
The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health
Nogal, A., Valdes, A. M., & Menni, C. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1897212 · Cited by 917
Short chain fatty acids: Microbial metabolites for gut-brain axis signalling
O’Riordan, K. J., Collins, M., Moloney, G. M., Knox, E. G., Aburto, M. R., Fülling, C., Morley, S. J., Clarke, G. A., Schellekens, H., & Cryan, J. F. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111572 · Cited by 788

See all 373

Authors: Silva, A. D., & Bloom, S. R.
Affiliations: Imperial College London (GB)
Corresponding author: Bloom, Stephen R.
ORCID: Bloom, Stephen R.
Venue: Gut and Liver
Publisher: The Editorial Office of Gut and Liver
Published: 2012-01-30
Volume: 6
Issue: 1
Pages: 10-20
ISSN: 1976-2283 (ISSN-L)
2005-1212
DOI: 10.5009/gnl.2012.6.1.10
PMC: PMC3286726
OpenAlex: W2004923528
Cited by: 373
References: 85
Citations by year: 2026: 29 · 2025: 46 · 2024: 22 · 2023: 19 · 2022: 31 · 2021: 23 · 2020: 36 · 2019: 36 · 2018: 32 · 2017: 23 · 2016: 20 · 2015: 16 · 2014: 18 · 2013: 15 · 2012: 7
FWCI: 7.99
Type: journal article
Language: en
Open access: diamond
doi.org
Licence: cc-by-nc
Locations: Gut and Liver (publishedVersion, cc-by-nc)
Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
PubMed Central (publishedVersion, cc-by-nc)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Spiral (Imperial College London) (submittedVersion, other-oa)
Topics: Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords: gastrointestinal hormones, appetite regulation, peptide YY, glucagon-like peptide-1, obesity, gastric bypass, food intake regulation, therapeutic target

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks